Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid

Summary

To explore the efficacy of Houyanqing Oral Liquid combined with conventional treatment in preventing and treating radiation-induced oral mucositis, so as to improve the quality of life of nasopharyngeal carcinoma patients received radiotherapy.

Conditions

• Nasopharyngeal Cancinoma (NPC)
• Radiation-induced Oral Mucositis

Interventions

DRUG

Houyanqing Oral Liquid

Houyanqing Oral Liquid is a Chinese herbal preparation formulated with Achyranthes aspera L., Kalimeris indica (L.) Sch.-Bip., Plantago asiatica L., and Carpesium abrotanoides L.. For this study, it is used in nasopharyngeal carcinoma patients receiving radical radiotherapy: the dosage is 10mL per administration, 4 times daily. The medication is initiated prior to radiotherapy and continued until the completion of radiotherapy, with the purpose of preventing and treating radiation-induced oral mucositis.

OTHER

Conventional Treatment for Radiation-Induced Oral Mucositis

This intervention refers to the conventional management measures for radiation-induced oral mucositis (RIOM) in nasopharyngeal carcinoma patients undergoing radical radiotherapy, including three modules: 1) Oral hygiene management; 2) Epithelial repair promotion; 3) Symptomatic support. These measures are implemented throughout the radiotherapy period to alleviate RIOM-related symptoms.

Sponsors & Collaborators

• Fujian Cancer Hospital

  collaborator OTHER_GOV

• Eye & ENT Hospital of Fudan University

  collaborator OTHER

• Zhejiang Cancer Hospital

  collaborator OTHER

• West China Hospital

  collaborator OTHER

• Yunnan Cancer Hospital

  collaborator OTHER

• First Affiliated Hospital of Kunming Medical University

  collaborator OTHER

• The First People's Hospital of Changzhou

  collaborator OTHER

• Xiangya Hospital of Central South University

  collaborator OTHER

• Affiliated Cancer Hospital of Shantou University Medical College

  collaborator OTHER

• Wuzhou Red Cross Hospital

  collaborator OTHER

• Hunan Cancer Hospital

  collaborator OTHER

• Cancer Hospital of Guangxi Medical University

  collaborator OTHER

• Affiliated Cancer Hospital & Institute of Guangzhou Medical University

  collaborator OTHER

• Sun Yat-Sen University Cancer Center

  collaborator OTHER

• Cancer Hospital Chinese Academy of Medical Science

  collaborator UNKNOWN

• The Fifth Affiliated Hospital, Sun Yat-sen University

  collaborator UNKNOWN

• Sun Yat-sen University

  lead OTHER

Principal Investigators

• Ming-Yuan Chen, MD, PhD · Fifth Affiliated Hospital of Sun Yat-sen University

Study Design

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

SINGLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

75 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2025-12-16

Primary Completion

2027-03-15

Completion

2027-08-15

Countries

• China

Study Locations